Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)
Institut de Cancérologie de Lorraine
Institut de Cancérologie de Lorraine
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
National Institutes of Health Clinical Center (CC)
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Jagiellonian University
Sichuan Cancer Hospital and Research Institute
Alliance for Clinical Trials in Oncology
Krankenhaus Nordwest
Bayer
Umeå University
Hospital Universitari de Bellvitge
Nova Scotia Health Authority
Apexigen America, Inc.
University Medical Center Groningen
First Affiliated Hospital, Sun Yat-Sen University
Emory University
National Cancer Centre, Singapore
First Affiliated Hospital, Sun Yat-Sen University
Cabrini Health
Ruijin Hospital
Goethe University
Universitätsklinikum Hamburg-Eppendorf
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Universitätsklinikum Hamburg-Eppendorf
Jagiellonian University
Zhejiang University
SCRI Development Innovations, LLC
Shanghai Minimally Invasive Surgery Center
Qilu Hospital of Shandong University
Sun Yat-sen University
Abramson Cancer Center at Penn Medicine
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
National Cancer Institute, Naples
Brown University
University of Alexandria
Radiation Therapy Oncology Group
M.D. Anderson Cancer Center
Medical University of Silesia
ChineseAMS
Maastricht Radiation Oncology
Celgene
King Faisal Specialist Hospital & Research Center
Peking University
Menoufia University
Seoul National University Hospital
Providence Health & Services
Wake Forest University Health Sciences
Northwestern University